{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:25:19Z","timestamp":1789464319033,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.rmr.2015.02.091","type":"journal-article","created":{"date-parts":[[2015,6,14]],"date-time":"2015-06-14T10:15:47Z","timestamp":1434276947000},"page":"867-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nouvelles cibles et nouvelles mol\u00e9cules en oncologie thoracique"],"prefix":"10.1016","volume":"32","author":[{"given":"D.","family":"Rouviere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-D.","family":"Milia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Guibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2015.02.091_bib0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.rmr.2015.02.091_bib0325","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.rmr.2015.02.091_bib0330","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes; the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.rmr.2015.02.091_bib0335","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112\u00a0cases of melanoma","volume":"15","author":"Greaves","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.rmr.2015.02.091_bib0340","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0345","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2015.02.091_bib0350","doi-asserted-by":"crossref","first-page":"A8000","DOI":"10.1200\/jco.2013.31.15_suppl.8000","article-title":"Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000\u00a0non-small cell lung cancer (NSCLC) patients (pts)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0355","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Paik","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0360","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2013.06.014","article-title":"Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma","volume":"82","author":"Sasaki","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0365","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","article-title":"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer","volume":"19","author":"Cardarella","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2015.02.091_bib0370","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/JTO.0b013e3182629903","article-title":"A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib","volume":"7","author":"Gautschi","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0375","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1200\/JCO.2012.47.6143","article-title":"Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma","volume":"31","author":"Peters","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0380","first-page":"1","article-title":"Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase\u00a0II trial BRF113923","volume":"25","author":"Planchard","year":"2014","journal-title":"ESMO 2014"},{"key":"10.1016\/j.rmr.2015.02.091_bib0385","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.lungcan.2013.08.012","article-title":"Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib","volume":"82","author":"Gautschi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0390","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/JTO.0b013e31828bb1b3","article-title":"Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer","volume":"8","author":"Rudin","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0395","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1002\/j.1460-2075.1995.tb00101.x","article-title":"Heregulin-dependent regulation of HER2\/neu oncogenic signaling by heterodimerization with HER3","volume":"14","author":"Wallasch","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.rmr.2015.02.091_bib0400","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","article-title":"The basic biology of HER2","volume":"12","author":"Rubin","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0405","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2\u00a0kinase domain in lung adenocarcinomas","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2015.02.091_bib0410","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2\u00a0kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.rmr.2015.02.091_bib0415","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1073\/pnas.0808930106","article-title":"HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992\u00a0and rapamycin combination therapy","volume":"106","author":"Perera","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rmr.2015.02.091_bib0420","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.1595","article-title":"Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas","volume":"28","author":"Zhou","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0425","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2011.01.014","article-title":"Prognostic and predictive implications of HER2\/ERBB2\/neu gene mutations in lung cancers","volume":"74","author":"Tomizawa","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0430","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The Battle trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.rmr.2015.02.091_bib0435","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1756-9966-28-97","article-title":"The effect of HER2\u00a0expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients","volume":"28","author":"Calikusu","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.rmr.2015.02.091_bib0440","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/01.JTO.0000268676.79872.9b","article-title":"EGFR and HER2\u00a0gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)","volume":"2","author":"Cappuzzo","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0445","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc060020","article-title":"HER2\u00a0mutation and response to trastuzumab therapy in non-small-cell lung cancer","volume":"354","author":"Cappuzzo","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2015.02.091_bib0450","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/JTO.0b013e3182904dfb","article-title":"Specificities of lung adenocarcinoma in women who have never smoked","volume":"8","author":"Mazieres","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0455","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2407-10-188","article-title":"Antitumor and antiangiogenic effect of the dual EGFR and HER-2\u00a0tyrosine kinase inhibitor lapatinib in a lung cancer model","volume":"10","author":"Diaz","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0460","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1078-0432.CCR-08-3328","article-title":"Randomized phase\u00a0II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer","volume":"16","author":"Ross","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2015.02.091_bib0465","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2\u00a0inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.rmr.2015.02.091_bib0470","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2012.01.008","article-title":"Clinical activity of afatinib (BIBW\u00a02992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2\/neu","volume":"76","author":"De Greve","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0475","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.2012.47.2787","article-title":"Phase\u00a0I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors","volume":"32","author":"Gandhi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0480","first-page":"1","article-title":"Neratinib (N) with our without temsirolimus (TEM) in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2\u00a0somatic mutations: An international randomized phase\u00a0II study","volume":"25","author":"Besse","year":"2014","journal-title":"ESMO"},{"key":"10.1016\/j.rmr.2015.02.091_bib0485","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.rmr.2015.02.091_bib0490","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0495","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.lungcan.2006.07.006","article-title":"PIK3CA mutation status in Japanese lung cancer patients","volume":"54","author":"Kawano","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0500","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/cncr.22677","article-title":"Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy","volume":"109","author":"Pantuck","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0505","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-10-0802","article-title":"Phase\u00a0II study of everolimus (RAD001) in previously treated small cell lung cancer","volume":"16","author":"Tarhini","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2015.02.091_bib0510","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cncr.22816","article-title":"Phase\u00a01\u00a0trial of everolimus and gefitinib in patients with advanced non small-cell lung cancer","volume":"110","author":"Milton","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0515","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdt536","article-title":"Phase\u00a0II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0520","doi-asserted-by":"crossref","first-page":"9270","DOI":"10.1073\/pnas.84.24.9270","article-title":"Expression and rearrangement of the ROS1\u00a0gene in human glioblastoma cells","volume":"84","author":"Birchmeier","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rmr.2015.02.091_bib0525","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.rmr.2015.02.091_bib0530","doi-asserted-by":"crossref","first-page":"e15640","DOI":"10.1371\/journal.pone.0015640","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2015.02.091_bib0535","doi-asserted-by":"crossref","first-page":"e28250","DOI":"10.1371\/journal.pone.0028250","article-title":"Chromosome\u00a03\u00a0anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours","volume":"6","author":"Birch","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2015.02.091_bib0540","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/cncr.27967","article-title":"Identification of ROS1\u00a0rearrangement in gastric adenocarcinoma","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2015.02.091_bib0545","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1\u00a0rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0550","first-page":"S1","article-title":"Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC)","volume":"8","author":"Sai-Hong","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0555","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2015.02.091_bib0560","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1\u00a0rearrangement: results from the EUROS1\u00a0cohort","volume":"33","author":"Mazieres","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0565","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s10637-011-9790-6","article-title":"Synergistic activity of the HSP90\u00a0inhibitor ganetespib with taxanes in non-small cell lung cancer models","volume":"30","author":"Proia","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.rmr.2015.02.091_bib0570","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-12-0440","article-title":"Targeted inhibition of the molecular chaperone HSP90\u00a0overcomes ALK inhibitor resistance in non-small cell lung cancer","volume":"3","author":"Sang","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.rmr.2015.02.091_bib0575","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.rmr.2015.02.091_bib0580","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ncponc0610","article-title":"Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy","volume":"3","author":"Drosten","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0585","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-08-2742","article-title":"Targeting the RET pathway in thyroid cancer","volume":"15","author":"Wells","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2015.02.091_bib0590","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1158\/1078-0432.CCR-12-0838","article-title":"Identification of KIF5B-RET and GOPC-ROS1\u00a0fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions","volume":"18","author":"Suehara","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2015.02.091_bib0595","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0600","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","article-title":"Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas","volume":"3","author":"Drilon","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.rmr.2015.02.091_bib0605","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.rmr.2015.02.091_bib0610","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.rmr.2015.02.091_bib0615","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/nm.2473","article-title":"A crucial requirement for Hedgehog signaling in small cell lung cancer","volume":"17","author":"Park","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.rmr.2015.02.091_bib0620","first-page":"S245","article-title":"Molecular multidisciplinary tumor board (MMTB) for lung cancer patients: 2-year experience report","volume":"8","author":"Besse","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0625","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.molonc.2012.02.008","article-title":"The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy","volume":"6","author":"Arnedos","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/j.rmr.2015.02.091_bib0630","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-012-0237-6","article-title":"Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial","volume":"7","author":"Le Tourneau","year":"2012","journal-title":"Target Oncol"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842515002272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842515002272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:49:50Z","timestamp":1599133790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842515002272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0761842515002272"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2015.02.091","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelles cibles et nouvelles mol\u00e9cules en oncologie thoracique","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2015.02.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 SPLF. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}